MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Pacira Pharmaceuticals Company Profile (NASDAQ:PCRX)

Consensus Ratings for Pacira Pharmaceuticals (NASDAQ:PCRX) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $104.67 (69.36% upside)

Current Analysts' Coverage Summary for Pacira Pharmaceuticals (NASDAQ:PCRX)
Show:
DateFirmActionRatingPrice TargetActions
7/27/2015Jefferies GroupReiterated RatingBuy$81.00 -> $72.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2015WedbushReiterated RatingBuy$116.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/19/2015Leerink SwannInitiated CoverageMarket Perform$86.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/28/2015Brean CapitalReiterated RatingBuy$92.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2015Canaccord GenuityLower Price TargetBuy$128.00 -> $89.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015BarclaysLower Price TargetOverweight$127.00 -> $115.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2015Bank of AmericaDowngradeNeutral -> Underperform$112.00 -> $110.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015Piper JaffraySet Price TargetBuy$136.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/30/2015Goldman SachsBoost Price Target$126.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2014JMP SecuritiesInitiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2014National Alliance SecuritiesInitiated CoverageBuy$109.41View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha